{"log_id": 7518897255967972835, "direction": 0, "words_result_num": 26, "words_result": [{"probability": {"variance": 4e-06, "average": 0.997586, "min": 0.993727}, "location": {"width": 152, "top": 245, "height": 37, "left": 177}, "words": "【药代动力学】"}, {"probability": {"variance": 1e-05, "average": 0.998285, "min": 0.981424}, "location": {"width": 781, "top": 277, "height": 60, "left": 217}, "words": "群体药代动力学分析汇总了在健康受试者和癌症患者中完成的17项试验的数据"}, {"probability": {"variance": 8.3e-05, "average": 0.996817, "min": 0.947091}, "location": {"width": 752, "top": 337, "height": 56, "left": 174}, "words": "采用有一级吸收和滞后时间的双室模型可充分描述阿昔替尼的浓度时间曲线"}, {"probability": {"variance": 0.000686, "average": 0.990277, "min": 0.860614}, "location": {"width": 804, "top": 389, "height": 57, "left": 218}, "words": "吸收和分布:以5mg剂量单次口服给药后,中位Tmax范围为2.5~4.1小时。根据血"}, {"probability": {"variance": 0.002332, "average": 0.986895, "min": 0.708602}, "location": {"width": 846, "top": 444, "height": 58, "left": 175}, "words": "浆半衰期,预计在给药后2~3天内达到稳态。与单次给药相比,阿昔替尼以5mg每日"}, {"probability": {"variance": 0.000583, "average": 0.993325, "min": 0.841337}, "location": {"width": 847, "top": 498, "height": 57, "left": 176}, "words": "给药两次,导致药物约1.4倍蓄积。稳态时,阿昔替尼在1mg~20mg剂量范围内表现出"}, {"probability": {"variance": 3.6e-05, "average": 0.997001, "min": 0.973009}, "location": {"width": 752, "top": 554, "height": 56, "left": 178}, "words": "线性药代动力学。口服5mg剂量后,阿昔替尼的平均绝对生物利用度为58%"}, {"probability": {"variance": 3.3e-05, "average": 0.997626, "min": 0.973791}, "location": {"width": 793, "top": 607, "height": 54, "left": 226}, "words": "与空腹过夜服用相比,阿昔替尼与中等脂肪膳食同服,结果导致AUC下降10%"}, {"probability": {"variance": 0.003608, "average": 0.981299, "min": 0.651001}, "location": {"width": 847, "top": 661, "height": 58, "left": 182}, "words": "与高脂肪、高热量膳食一同给药,结果导致AUC升高19%。阿昔替尼可与食物同服或"}, {"probability": {"variance": 0.000387, "average": 0.987956, "min": 0.935166}, "location": {"width": 273, "top": 733, "height": 41, "left": 182}, "words": "空腹给药(见【用法用量】)"}, {"probability": {"variance": 0, "average": 0.90285, "min": 0.90285}, "location": {"width": 186, "top": 689, "height": 71, "left": 895}, "words": "不"}, {"probability": {"variance": 0.00032, "average": 0.993968, "min": 0.889031}, "location": {"width": 806, "top": 769, "height": 57, "left": 226}, "words": "阿昔替尼与人血浆蛋白高度结合(>99%),优先与白蛋白结合,与a1-酸性球蛋白"}, {"probability": {"variance": 0.000159, "average": 0.991775, "min": 0.957211}, "location": {"width": 836, "top": 825, "height": 57, "left": 185}, "words": "的结合率适中。在晚期RCC患者(n=20)中,在进食状态下每日给予两次5mg剂量"}, {"probability": {"variance": 0.005412, "average": 0.964639, "min": 0.714453}, "location": {"width": 821, "top": 883, "height": 54, "left": 185}, "words": "Cmax和AUC24的几何平均值(CV%)分别为27.8(79%)ng/mL、265(77%)ng./mL"}, {"probability": {"variance": 0.000602, "average": 0.987589, "min": 0.861202}, "location": {"width": 829, "top": 934, "height": 56, "left": 185}, "words": "清除率和表观分布容积的几何平均值(CV%)分别为38(80%)L/h、160(105%)L"}, {"probability": {"variance": 0.001012, "average": 0.989526, "min": 0.8447}, "location": {"width": 805, "top": 989, "height": 56, "left": 232}, "words": "代谢和排泄:阿昔替尼的血浆半衰期范围为2.5~6.1小时。阿昔替尼主要经肝脏"}, {"probability": {"variance": 0.006159, "average": 0.967138, "min": 0.656831}, "location": {"width": 844, "top": 1043, "height": 57, "left": 192}, "words": "CYP3A4/5代谢,少量经CYP1A2、CYP2C19、UGT1A1代谢。当阿昔替尼以5mg放射"}, {"probability": {"variance": 3.5e-05, "average": 0.997238, "min": 0.973919}, "location": {"width": 825, "top": 1097, "height": 57, "left": 190}, "words": "活性剂量口服给药后,约41%放射活性从粪便中回收,有23%放射活性从尿液中回收"}, {"probability": {"variance": 0.003915, "average": 0.986835, "min": 0.604523}, "location": {"width": 848, "top": 1151, "height": 58, "left": 190}, "words": "阿昔替尼原形药物(占给药剂量的12%)是粪便中确认的主要成分;羧酸代谢产物和亚"}, {"probability": {"variance": 5.4e-05, "average": 0.996826, "min": 0.961264}, "location": {"width": 849, "top": 1206, "height": 57, "left": 194}, "words": "砜代谢产物占尿液中放射活性的绝大多数。在血浆中,N葡萄糖醛酸代谢产物代表主要"}, {"probability": {"variance": 1e-05, "average": 0.997821, "min": 0.985746}, "location": {"width": 851, "top": 1261, "height": 61, "left": 193}, "words": "放射活性成分(占循环放射活性的50%),阿昔替尼原形药物和亚砜代谢产物各占循环"}, {"probability": {"variance": 7e-06, "average": 0.997921, "min": 0.992352}, "location": {"width": 164, "top": 1345, "height": 30, "left": 197}, "words": "放射活性的20%"}, {"probability": {"variance": 0.001537, "average": 0.990535, "min": 0.768344}, "location": {"width": 801, "top": 1373, "height": 57, "left": 244}, "words": "与阿昔替尼相比,亚砜代谢产物和N葡萄糖醛酸代谢产物作用于 VEGFR-2的体外"}, {"probability": {"variance": 2.8e-05, "average": 0.997979, "min": 0.978314}, "location": {"width": 300, "top": 1448, "height": 40, "left": 198}, "words": "效价降低400倍或400倍以上"}, {"probability": {"variance": 1.3e-05, "average": 0.996538, "min": 0.987959}, "location": {"width": 139, "top": 1587, "height": 26, "left": 560}, "words": "第24页,共27页"}, {"probability": {"variance": 0.005642, "average": 0.969142, "min": 0.744456}, "location": {"width": 90, "top": 1624, "height": 21, "left": 263}, "words": "No:2015042"}], "language": 3}